TechnoPhage, SA - From science to innovative biopharmaceuticals
In 2019, Technophage was among the top 100 companies with the highest R&D investment in Portugal. According to the provisional results of the IPCTN19, the 100 companies or groups with more intramural investment in R&D are responsible for 47% of the total investment in R&D of the business sector in 2019, which reached…
TechnoPhage owns an innovative unit for the production of biological medicines that has now obtained authorization from INFARMED for the manufacture and analysis of medicines, becoming one of the few in the country with this capacity. The unit established in Venda Nova (Amadora) will manufacture, at this stage, biological medicines for use in…
COVID-19 New Challenge: joint effort to mitigate world’s pandemic crisis (TechnoPhage S.A., Faculty of Pharmacy of University of Lisbon and Vector B2B – Drug Developing Association for Research in Biotechnology) In Portugal, we have highly qualified human resources working in biological drug discovery and development. In a joint effort to tackle COVID-19 we…
Since the 1st January 2020, Technophage is a resident company of Johnson & Johnson Innovation, JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As…

2019 events

Phage Futures Europe
Brussels, Belgium, September 25-26, 2019